ERBB2 and neoplasm: CLTX was demonstrated to bind the majority of tumor cells in more than 90% of tested tumor samples, with little to no reactivity with healthy brain and independently from the expression of other targets as IL-13Rα2, EGFRvIII, and HER2 (ref. [135]).